Kevin Ault, M.D.

Ault KA and the FUTURE II Study Group. Prophylactic use of human papillomavirus (HPV) L1 virus-like particle vaccine significantly reduces cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ risk: a combined analysis of four efficacy trials. The Lancet 2007,369:1861-1868.

Fraser C, Tomassini J, Xi L, Golm G, Watson M, Giuliano A, Barr E and Ault KA. Modeling the Long-term Antibody Response of a Human Papillomavirus (HPV) Virus-like Particle (VLP) Type 16 Prophylactic Vaccine. Vaccine,2007; 25:4324-4333.

Hollmer C, Essmann M, Ault KA and Larsen B. Adherence and Blocking of Candida albicans to Cultured Vaginal Epithelial Cells: Treatments to Decrease Adherence. Infectious Diseases in Obstetrics and Gynecology,2006; Article ID 98218. (on line journal).

Koutsky L and the FUTURE II Study Group (including Ault KA). Efficacy and safety of a prophylactic quadrivalent human papillomavirus (types 6/11/16/18) L1 virus-like-particle vaccine in the prevention of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a randomized controlled trial . N Engl J Med 2007,356:1915-1927.

Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA et al. Immunologic Responses following Administration of a Vaccine Targeting Human Papillomavirus Types 6, 11, 16, and 18. Vaccine,2006; 24:5571 � 5583.